Analytical Data
-
基因名
VEGF165
-
简介
VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is 165 a.a., with molecular weight of 28-32 kDa.
- Application
-
别名
VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15692-4
-
表达区间
A27-R191
-
蛋白长度
Partial
-
分子量
28-35 kDa under reduced (R) conditions, 45-60 kDa under non reducing (N) conditions, based on SDS-PAGE,.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular endothelial growth factor (VEGF) is a critical signaling protein that plays a significant role in angiogenesis, the formation of new blood vessels from pre-existing ones. Among its isoforms, VEGF165 is the most abundant and biologically active variant, which has been extensively studied for its involvement in various physiological and pathological processes, including embryonic development, wound healing, and tumor growth. The dysregulation of VEGF165 expression is linked to several diseases, particularly cancer, where it promotes tumor angiogenesis, facilitating tumor growth and metastasis. Consequently, VEGF165 has emerged as a potential therapeutic target, leading to the development of anti-angiogenic therapies aimed at inhibiting its function. Recombinant VEGF165 protein has been utilized in research to elucidate its mechanisms of action, assess its role in cellular signaling pathways, and evaluate its effects on endothelial cell proliferation and migration. The production of recombinant VEGF165 in various expression systems, including bacterial, yeast, and mammalian cells, has allowed for detailed studies of its biochemical properties and biological activities. Understanding the structure-function relationship of VEGF165 is crucial for designing specific inhibitors or modulators that can effectively interfere with its signaling in pathological conditions, thereby providing new strategies for treating diseases associated with abnormal angiogenesis. Overall, the study of recombinant VEGF165 protein not only enhances our understanding of vascular biology but also paves the way for novel therapeutic interventions in cancer and other angiogenesis-related diseases.
